About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Mr. Alexander describes the importance of blood-conservation strategies, including the use of drugs, that can be beneficial during procedures such as transfusions and coronary artery bypass grafting.
Walter Alexander, MS
American Society of Hematology State-of-the-Art Symposium: Myeloma and Lymphoma: Recent Advances in Biology and Therapy
Progress is being made in the way tumors are being targeted by agents such as lenalidomide, bortezomib, rituximab, and a variety of other novel chemotherapeutic regimens.
Marvin M. Goldenberg, PhD, RPh, MS
The Prescotts discuss hormonal replacement therapy; lasofoxifene for vaginal atrophy; testosterone for low libido; alendronate, transdermal estrogen, risedronate, and ibandronate for osteoporosis; and the transdermal oxybutynin patch for overactive bladder.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Continuing Education Credit
When switching patients from one selective serotonin reuptake inhibitor to another, health care providers need to consider several factors, namely, the pharmacokinetic profile of the current drug, the possibility of serotonin syndrome, and withdrawal symptoms.
Kristin Zerumsky, PharmD, Rae Ann Maxwell, RPh, PhD, and Nicole T. Ansani, PharmD
David Nash, MD, MBA, questions whether the widespread use of proton pump inhibitors is creating new problems, including the risk of Clostridium difficile infection.
David B. Nash, MD, MBA
Stephen Barlas discusses problems with Medicare’s interim electronic prescribing standards, which exclude protocols that would have allowed PBMs and physicians to exchange important information.
Matthew Grissinger, RPh, FASCP, discusses the dangers of stray and intentional marks on prescription order forms.
Matthew Grissinger, RPh, FASCP
Dr. Small reviews an immediate-release formulation of the proton pump inhibitor omeprazole (Zegerid®) for the treatment of gastric acid–related disorders.
Ralph E. Small, PharmD
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.